@article{45d583a0d23546c183e0249ea5c1edf6,
title = "Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls",
abstract = "This study assessed relationships among white matter hyperintensities (WMH), cerebrospinal fluid (CSF), Alzheimer's disease (AD) pathology markers, and brain volume loss. Subjects included 197 controls, 331 individuals with mild cognitive impairment (MCI), and 146 individuals with AD with serial volumetric 1.5-T MRI. CSF Aβ1-42 (n = 351) and tau (n = 346) were measured. Brain volume change was quantified using the boundary shift integral (BSI). We assessed the association between baseline WMH volume and annualized BSI, adjusting for intracranial volume. We also performed multiple regression analyses in the CSF subset, assessing the relationships of WMH and Aβ1-42 and/or tau with BSI. WMH burden was positively associated with BSI in controls (. p = 0.02) but not MCI or AD. In multivariable models, WMH (. p = 0.003) and Aβ1-42 (. p = 0.001) were independently associated with BSI in controls; in MCI Aβ1-42 (. p < 0.001) and tau (. p = 0.04) were associated with BSI. There was no evidence of independent effects of WMH or CSF measures on BSI in AD. These data support findings that vascular damage is associated with increased brain atrophy in the context of AD pathology in pre-dementia stages.",
keywords = "Alzheimer's disease, Mild cognitive impairment (MCI), Normal aging, Vascular disease, Volumetric MRI",
author = "Josephine Barnes and Carmichael, {Owen T.} and Leung, {Kelvin K.} and Christopher Schwarz and Ridgway, {Gerard R.} and Bartlett, {Jonathan W.} and Malone, {Ian B.} and Schott, {Jonathan M.} and Rossor, {Martin N.} and Biessels, {Geert Jan} and Charlie DeCarli and Fox, {Nick C.}",
note = "Funding Information: This work was supported by the Medical Research Council [grant numbers GO 601846, MR/J014257/1 ]. JMS is a HEFCE/NHS Clinical Senior Lecturer and is supported by the Alzheimer Research UK . The research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Dementia based at University College London Hospitals (UCLH), University College London (UCL). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Dementia Research Centre is an Alzheimer's Research UK Co-ordinating Centre. This work was made possible with an Alzheimer's Research UK Equipment Grant. The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust [grant number 091593/Z/10/Z ]. Funding Information: Josephine Barnes: Dr Barnes has received honoraria for reviewing grants for the Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia-Portugal and was supported by an Alzheimer's Research UK fellowship. Funding Information: Gerard R Ridgway: Dr Ridgway serves as an editorial board member for NeuroImage and has received honoraria for teaching on SPM courses. Jonathan M Schott: Dr Schott is a UK HEFCE Senior Lecturer and receives grant support from Alzheimer's Research UK Martin N Rossor: Professor Martin Rossor sits on the Data Monitoring Committee for Servier DMC Phase 2B AD Study S38093, and also sits on the Bapineuzumab Independent Safety Monitoring Committee for Janssen Al/Pfizer. Charlie DeCarli: Dr DeCarli is editor-in-Chief of ADAD. He has received honoraria for speaking at various academic centers and teaching at the AAN and has consulted with Avid and Takeda over the last year. Nick C Fox: Dr Fox has served on the scientific advisory boards of Alzheimer's Research Forum, Alzheimer's Society and Alzheimer's Research Trust and editorial boards of Alzheimer's Disease and Associated Disorders, Neurodegenerative Diseases, and Alzheimer's Research and Therapy. He holds a patent for QA Box that may accrue revenue. In the last 5 years his research group has received payment for consultancy or for conducting studies from Abbott Laboratories, AstraZeneca, AVID, Bristol-Myers Squibb, Elan Pharmaceuticals, Eisai, Eli Lilly, GE Healthcare, IXICO, Janssen (JAI), Lundbeck, Neurochem Inc, Pfizer Inc, Sanofi-Aventis, Teva and Wyeth Pharmaceuticals. He receives research support from MRC [G0801306 (PI), G0601846 (PI)] NIH [U01 AG024904 (Co-investigator(sub contract)], Alzheimer Research Trust [ART/RF/2007/1 (PI)] and NIHR (Senior Investigator). None of the other authors have any conflicts of interest to declare. ",
year = "2013",
month = aug,
doi = "10.1016/j.neurobiolaging.2013.02.003",
language = "English (US)",
volume = "34",
pages = "1996--2002",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "8",
}